IN2012DN05014A - - Google Patents

Download PDF

Info

Publication number
IN2012DN05014A
IN2012DN05014A IN5014DEN2012A IN2012DN05014A IN 2012DN05014 A IN2012DN05014 A IN 2012DN05014A IN 5014DEN2012 A IN5014DEN2012 A IN 5014DEN2012A IN 2012DN05014 A IN2012DN05014 A IN 2012DN05014A
Authority
IN
India
Prior art keywords
moieties
vegf
ectodomain
antagonize
receptors
Prior art date
Application number
Inventor
Joseph Schlessinger
Yan Yang
Original Assignee
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale filed Critical Univ Yale
Publication of IN2012DN05014A publication Critical patent/IN2012DN05014A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/01—Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Abstract

The present invention provides moieties that bind to the most membrane- proximal Ig-like domain of the ectodomain (D7) of vascular endothelial growth factor (VEGF) receptors, wherein the moieties antagonize the activity of the VEGF receptor.
IN5014DEN2012 2009-12-29 2010-12-20 IN2012DN05014A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29078909P 2009-12-29 2009-12-29
PCT/US2010/061296 WO2011090648A2 (en) 2009-12-29 2010-12-20 Inhibitors of vascular endothelial growth factor (vegf) receptors and methods of use thereof

Publications (1)

Publication Number Publication Date
IN2012DN05014A true IN2012DN05014A (en) 2015-10-02

Family

ID=44307462

Family Applications (1)

Application Number Title Priority Date Filing Date
IN5014DEN2012 IN2012DN05014A (en) 2009-12-29 2010-12-20

Country Status (14)

Country Link
US (1) US20130071397A1 (en)
EP (1) EP2519253A4 (en)
JP (1) JP2013515776A (en)
KR (1) KR20120115348A (en)
CN (1) CN102724996A (en)
AU (1) AU2010343193A1 (en)
BR (1) BR112012016309A2 (en)
CA (1) CA2785723A1 (en)
IL (1) IL220147A0 (en)
IN (1) IN2012DN05014A (en)
MX (1) MX2012007745A (en)
RU (1) RU2012132470A (en)
SG (1) SG181495A1 (en)
WO (1) WO2011090648A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103694351A (en) 2007-06-05 2014-04-02 耶鲁大学 Inhibitors of receptor tyrosine kinases and methods of use thereof
US9540443B2 (en) 2011-01-26 2017-01-10 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies
CN104650229A (en) * 2011-11-02 2015-05-27 埃派斯进有限公司 Anti-KDR antibodies and methods of use
BR112015001459B1 (en) 2012-07-25 2023-02-14 Celldex Therapeutics, Inc ISOLATED ANTIBODY OR FRAGMENT THEREOF, CONJUGATE, USES THEREOF, PHARMACEUTICAL COMPOSITION, POLYNUCLEOTIDE, VECTOR, HOST CELL, ISOLATED CELL, KIT, IN VITRO METHOD TO INHIBIT KIT ACTIVITY, METHOD TO PRODUCE AN ANTIBODY
AU2014342065B2 (en) * 2013-11-01 2019-01-03 Atrium Medical Corporation Positioning agent and method of using the same
CN113975386A (en) 2014-05-23 2022-01-28 塞尔德克斯医疗公司 Treatment of eosinophil or mast cell related disorders
CN104356226B (en) * 2014-11-04 2017-03-29 青岛海兰深生物科技有限公司 A kind of antigen polypeptide of detection blood plasma immunological marker thing VEGFR1 autoantibodys and application
CN108101986B (en) * 2015-01-06 2020-04-17 珠海亿胜生物制药有限公司 anti-VEGF antibodies
CN105820245B (en) * 2015-01-06 2018-03-13 珠海亿胜生物制药有限公司 anti-VEGF antibody
GB201612520D0 (en) * 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
CA3063719A1 (en) 2017-05-19 2018-11-22 The Regents Of The University Of California Antibody chemically induced dimerizer (abcid) as molecular switches for regulating cellular therapies
CA3068121A1 (en) * 2017-06-23 2018-12-27 Baxalta Incorporated Purification of factor viii subspecies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6448077B1 (en) * 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
EP1916001B1 (en) * 2002-03-04 2011-05-25 Imclone LLC Human antibodies specific to KDR and uses thereof
CN103694351A (en) * 2007-06-05 2014-04-02 耶鲁大学 Inhibitors of receptor tyrosine kinases and methods of use thereof
KR100883430B1 (en) * 2007-06-13 2009-02-12 한국생명공학연구원 Human Monoclonal Antibody Neutralizing Vesicular Endothelial Growth Factor Receptor and Use Thereof

Also Published As

Publication number Publication date
AU2010343193A1 (en) 2012-06-21
KR20120115348A (en) 2012-10-17
WO2011090648A3 (en) 2012-01-05
MX2012007745A (en) 2012-11-23
BR112012016309A2 (en) 2017-04-18
EP2519253A2 (en) 2012-11-07
JP2013515776A (en) 2013-05-09
US20130071397A1 (en) 2013-03-21
CN102724996A (en) 2012-10-10
WO2011090648A2 (en) 2011-07-28
SG181495A1 (en) 2012-07-30
CA2785723A1 (en) 2011-07-28
RU2012132470A (en) 2014-02-10
EP2519253A4 (en) 2013-08-07
IL220147A0 (en) 2012-07-31

Similar Documents

Publication Publication Date Title
IN2012DN05014A (en)
EA201101165A1 (en) CONNECTIONS MODULATING THE ACTIVITY OF Toll-like RECEPTORS
MX2011011825A (en) Humanized axl antibodies.
GB201017345D0 (en) Receptor antagonists
MX2010005031A (en) Axl antibodies.
SMT201600216B (en) OCTAIDROPIRROL [3,4.C] PIRROLS DISTRIBUTED AS MODULATORS OF OREXINA RECEPTOR
MX353706B (en) Antibodies binding preferentially human csf1r extracellular domain 4 and their use.
EP2271341A4 (en) Specific inhibitors for vascular endothelial growth factor receptors
UA117801C2 (en) Low affinity blood brain barrier receptor antibodies and uses therefor
MX2012003521A (en) Insulin receptor binding antibodies.
ATE496051T1 (en) PYRAZOLOTETRAHYDROPYRIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS
EP2560684A4 (en) Fibronectin type iii domain-based multimeric scaffolds
EA201290940A1 (en) NEW CONNECTIONS AS SELECTIVE ANTAGONISTS OF NK3 RECEPTOR, PHARMACEUTICAL COMPOSITION AND METHODS OF THEIR USE FOR DAMAGE MEDIATED BY NK3 RECEPTORS
IL207130A (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
BRPI1013821A2 (en) substituted pyridines as ccr3 antagonists.
MX2011011127A (en) 3 -azabicyclo [4.1.0] heptanes used as orexin antagonists.
GB2460597B8 (en) N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors
TN2011000639A1 (en) Compounds which selectively modulate the cb2 receptor
WO2010070658A3 (en) Improved process for the preparation of endothelin receptor antagonists
EA201171074A1 (en) CYTOTOXIC CONJUGATES WITH CONNECTION, BINDING THE NEUROPEPTIDE Y RECEPTOR
TR201903403T4 (en) Immunoglobulin preparation.
WO2012093809A3 (en) New bicyclic compound for modulating g protein-coupled receptors
HK1149003A1 (en) 4-aminopyrimidine derivatives as histamine h4 receptor antagonists
MX2010007669A (en) Methods for inhibiting angiogenesis using egfl8 antagonists.
UA107596C2 (en) A SELECTED POLYPEPTIDE CONNECTING TO THE INSULIN-FACTOR RECEPTOR 1